Needle and syringe sharing among people who have recently injected drugs in Australia: The ETHOS Engage Study.
HCV
PWID
recurrence
re‐infection
treatment
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
17 Apr 2024
17 Apr 2024
Historique:
revised:
01
01
2024
received:
29
06
2023
accepted:
10
02
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
17
4
2024
Statut:
aheadofprint
Résumé
Understanding needle/syringe sharing is crucial for reducing hepatitis C virus (HCV) infection and reinfection. This study aimed to assess the prevalence and factors associated with needle/syringe sharing among people who inject drugs in Australia, including those previously receiving HCV treatment. The ETHOS Engage study was an observational cohort study which collected self-reported survey data on demographic and drug use information from people who inject drugs attending drug treatment clinics and needle and syringe programs over two waves between May 2018 and June 2021. Logistic regression was used to identify factors associated with needle/syringe sharing. Overall, 1555/2395 people enrolled in ETHOS Engage (65%) injected drugs in the past month. Among these, 432 (28%) reported needle/syringe sharing in the past month and 276 (18%) reported receptive sharing. Factors associated with receptive sharing included younger age (adjusted odds ratio [aOR] 1.72; 95% confidence interval [CI] 1.28-2.30), recent incarceration (aOR 2.04; 95% CI 1.40-2.94), more frequent injecting (≥daily vs. less than weekly; aOR 2.59; 95% CI 1.75-3.84) and unstable housing (aOR 1.78; 95% CI 1.26-2.52). Among 560 participants with prior HCV treatment, 87 (16%) reported receptive sharing with younger age (aOR 2.42; 95% CI 1.45-4.05) and daily or greater injection frequency (aOR 2.51; 95% CI 1.31-4.83) associated with receptive sharing. Needle/syringe sharing was common among this population accessing harm reduction services. This study identifies high-risk populations with needle/syringe sharing. Research is needed to optimise HCV treatment to ensure people with ongoing risk behaviours receive adequate harm reduction following treatment to prevent reinfection.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Health and Medical Research Council
ID : 1103165
Organisme : New South Wales Health
Organisme : Merck Sharp and Dohme Australia
Organisme : Cepheid
Informations de copyright
© 2024 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.
Références
Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192–e1207.
Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country‐level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5:e1208–e1220.
Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta‐analysis. J Hepatol. 2020;72:643–657.
World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. Geneva, Licence: CC BY‐NC‐SA 30 IGO., 2021.
Tran LT, Peacock A, Colledge S, Memedovic S, Grebely J, Leung J, et al. Injecting risk behaviours amongst people who inject drugs: a global multi‐stage systematic review and meta‐analysis. Int J Drug Policy. 2020;84:102866.
Cunningham EB, Hajarizadeh B, Amin J, Bretana N, Dore GJ, Degenhardt L, et al. Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: the HITS‐p study. Int J Drug Policy. 2018;54:18–25.
Valerio H, Alavi M, Silk D, Treloar C, Martinello M, Milat A, et al. Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: the ETHOS engage study. Clin Infect Dis. 2021;73:e69–e78.
Valerio H, Alavi M, Conway A, Silk D, Treloar C, Martinello M, et al. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: the ETHOS engage study. Int J Drug Policy. 2022;105:103706.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT‐C): an effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158:1789–1795.
Heard S, Iversen J, Geddes L, Maher L. Australian needle syringe program survey national data report 2016–2020: prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: Kirby Institute, UNSW Sydney; 2021.
Martinello M, Dore GJ, Matthews GV, Grebely J. Strategies to reduce hepatitis C virus reinfection in people who inject drugs. Infect Dis Clin N Am. 2018;32:371–393.
Horyniak D, Dietze P, Degenhardt L, Higgs P, McIlwraith F, Alati R, et al. The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. Drug Alcohol Depend. 2013;132:541–546.
Colledge S, Leung J, Larney S, Peacock A, Grebely J, Hickman M, et al. Frequency of injecting among people who inject drugs: a systematic review and meta‐analysis. Int J Drug Policy. 2020;76:102619.
Samo RN, Altaf A, Agha A, Pasha O, Rozi S, Memon A, et al. High HIV incidence among persons who inject drugs in Pakistan: greater risk with needle sharing and injecting frequently among the homeless. PLoS One. 2013;8:e81715.
Bozinoff N, Wood E, Dong H, Richardson L, Kerr T, DeBeck K. Syringe sharing among a prospective cohort of street‐involved youth: implications for needle distribution programs. AIDS Behav. 2017;21:2717–2725.
Bardwell G, Boyd J, Kerr T, McNeil R. Negotiating space & drug use in emergency shelters with peer witness injection programs within the context of an overdose crisis: a qualitative study. Health Place. 2022;53:86–93.
Zakaria A, Abuabara K, Szumowski J, Kim‐Lim P, Fox LP, Amerson EH, et al. Association between homelessness and group a streptococcus skin and soft tissue infections among hospitalized dermatology consult patients. JAMA Dermatol. 2022;158:321–323.
Taweh N, Schlossberg E, Frank C, Nijhawan A, Kuo I, Knight K, et al. Linking criminal justice‐involved individuals to HIV, hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: progress, gaps, and future directions. Int J Drug Policy. 2021;96:103283.
Hajarizadeh B, Grebely J, Byrne M, Marks P, Amin J, McManus H, et al. Evaluation of hepatitis C treatment‐as‐prevention within Australian prisons (SToP‐C): a prospective cohort study. Lancet Gastroenterol Hepatol. 2021;6:533–546.
Bharat C, Webb P, Wilkinson Z, McKetin R, Grebely J, Farrell M, et al. Agreement between self‐reported illicit drug use and biological samples: a systematic review and meta‐analysis. Addiction. 2023;118:1624–1648.
Rance J, Rhodes T, Fraser S, Bryant J, Treloar C. Practices of partnership: negotiated safety among couples who inject drugs. Health. 2018;22:3–19.